Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Relmada Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
RLMD
Nasdaq
8731
https://www.relmada.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Relmada Therapeutics Inc
Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q4 2023 Earnings Call Transcript
- Mar 20th, 2024 2:27 pm
Q4 2023 Relmada Therapeutics Inc Earnings Call
- Mar 20th, 2024 10:27 am
Relmada Therapeutics Inc Reports Full-Year and Q4 2023 Financial Results
- Mar 19th, 2024 9:31 pm
Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results
- Mar 19th, 2024 8:15 pm
Relmada Therapeutics to Report Fourth Quarter and Full-Year 2023 Financial Results and Host Conference Call and Webcast on March 19, 2024
- Mar 12th, 2024 11:30 am
Relmada Therapeutics to Participate in the Leerink Partners Global Biopharma Conference
- Mar 5th, 2024 12:30 pm
Is Relmada Therapeutics (NASDAQ:RLMD) In A Good Position To Invest In Growth?
- Mar 4th, 2024 10:30 am
Relmada Therapeutics Inc CEO Sergio Traversa Acquires 100,000 Shares
- Feb 1st, 2024 8:02 pm
Relmada Therapeutics CEO & Director Acquires 69% More Stock
- Feb 1st, 2024 10:00 am
Relmada Therapeutics, Inc.'s (NASDAQ:RLMD) market cap touched US$109m last week, benefiting both individual investors who own 39% as well as institutions
- Jan 23rd, 2024 10:42 am
Relmada Therapeutics Provides Corporate Update
- Jan 4th, 2024 12:30 pm
11 Best Psychedelic Stocks to Buy in 2024
- Dec 29th, 2023 1:47 pm
Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q3 2023 Earnings Call Transcript
- Nov 10th, 2023 6:57 pm
Relmada Therapeutics Inc (RLMD) Reports Third Quarter 2023 Financial Results
- Nov 8th, 2023 11:47 pm
Relmada Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results
- Nov 8th, 2023 9:01 pm
Positive Signs As Multiple Insiders Buy Relmada Therapeutics Stock
- Nov 6th, 2023 1:25 pm
Relmada Therapeutics to Report Third Quarter 2023 Financial Results and Host Conference Call and Webcast on November 8, 2023
- Nov 3rd, 2023 11:30 am
Relmada Therapeutics to Present New Preclinical Data on its Psilocybin Program at AASLD The Liver MeetingĀ® 2023
- Oct 11th, 2023 12:30 pm
Relmada Therapeutics to Participate in the Jefferies Inaugural Biotech CNS/Neuro Summit
- Oct 9th, 2023 11:30 am
Relmada Therapeutics to Present Data from its REL-1017 and Psilocybin Programs at the 36th European College of Neuropsychopharmacology (ECNP) Congress
- Oct 6th, 2023 11:30 am
Scroll